ライフサイエンスコーパス: complement receptor

1 the presence of blocking Abs to FcgammaR and complement receptor.

2 fects B lymphocytes through their CD21 (CR2) complement receptor.

3 be eliminated by microglial cells expressing complement receptors.

4 sulting in vesicle recognition by macrophage complement receptors.

5 Ig receptors (FcRgammaI and FcgammaRIII) or complement receptors.

6 sonization and binding of these complexes to complement receptors.

7 , FcgammaRIV, the inhibitory FcgammaRIIB and complement receptors.

8 ility of bound C3 fragments to interact with complement receptor 1 (CD35) on the membrane of human er

9 psonized particles become immune adherent to complement receptor 1 (CR1 or CD35) on human erythrocyte

10 ly lack the third component of complement or complement receptor 1 (CR1) and CR2 developed increased

11 levels of E-bound Abs, reduced E-associated complement receptor 1 (CR1) and decay-accelerating facto

12 Complement receptor 1 (CR1) expressed on the surface of

13 Clustering of Complement Receptor 1 (CR1) in the erythrocyte membrane

14 Complement receptor 1 (CR1) is an Alzheimer's disease (A

15 Complement receptor 1 (CR1) on human erythrocytes (Es) a

16 ng protein-like homologue 4 (PfRh4) binds to complement receptor 1 (CR1) to mediate entry of malaria

17 veral receptors, including sialic acid (SA), complement receptor 1 (CR1), and basigin.

18 omplement-regulatory proteins, in particular complement receptor 1 (CR1), are important in the pathog

19 regulators decay-accelerating factor (DAF), complement receptor 1 (CR1), factor H, and C4-binding pr

20 iated with unusual deposits located near the complement receptor 1 (CR1)-expressing podocytes.

21 to phagocytes by human erythrocytes bearing complement receptor 1 (CR1).

22 immune complexes via erythrocytes expressing complement receptor 1 (CR1).

23 native LDL and acetylated LDL (acLDL) to the complement receptor 1 (CR1).

24 D55), membrane cofactor protein (MCP, CD46), complement receptor 1 (CR1, CD35) and viral molecules su

25 r primates are unique among mammals in using complement receptor 1 (CR1, CD35) on red blood cells (RB

26 During this process, RBCs use complement receptor 1 (CR1, CD35) to bind circulating co

27 ce or absence of blocking Abs to CD23, CD32, complement receptor 1 (CR1, CD35), and/or CR2 (CD21) was

28 The primary identified function of complement receptor 1 (CR1/CD35) on primate erythrocytes

29 , membrane cofactor protein (MCP; CD46), and complement receptor 1 (CR1; CD35).

30 ility of a human recombinant soluble form of complement receptor 1 (sCR1) to inhibit complement-media

31 ned approach was augmented by adding soluble complement receptor 1 (sCR1) to the perfusate in one fur

32 tabilized C3bBb and perturbed C3b binding to complement receptor 1 but did not perturb binding to fac

33 the recognition of deposited C3 fragments by complement receptor 1 even when the absolute number of C

34 -tetanus toxoid antibody levels, erythrocyte complement receptor 1 expression, and lymphocyte prolife

35 ynonymous SNP, rs6691117 (Val-->IIe), in the complement receptor 1 gene (CR1) was associated with ESR

36 s functions analogously to human erythrocyte complement receptor 1 in its role to traffic immune comp

37 up had a progressive increase in erythrocyte complement receptor 1 levels compared with baseline (P =

38 Complement receptor 1 levels on erythrocytes (ECR1) toge

39 o evaluate new therapeutic targets employing complement receptor 1 peptide homologues and the antimac

40 the functional analogue to human erythrocyte complement receptor 1 with a role that is distinct from

41 negative complement regulators Factor H and complement receptor 1 with C3b.

42 factors, such as decay accelerating factor, complement receptor 1, and factor H, which directly inte

43 tors, such as factor H, C4b-binding protein, complement receptor 1, and membrane cofactor protein.

44 on host cells by the complement system, and complement receptor 1-like protein y (CRRY) is an import

45 for the rodent complement regulatory protein complement receptor 1-related gene/protein y (Crry) (Crr

46 Complement receptor 1-related gene/protein y (Crry) and

47 Decay-accelerating factor (DAF) and complement receptor 1-related gene/protein y (Crry) are

48 In a model system in which RBCs deficient in complement receptor 1-related gene/protein y (Crry) are

49 Complement receptor 1-related gene/protein y (Crry) in r

50 of either decay-accelerating factor (DAF) or complement receptor 1-related gene/protein y (Crry) on m

51 e in vivo, using the C3 convertase inhibitor complement receptor 1-related gene/protein y (Crry)-Ig,

52 lement inhibition with complement receptor 2-complement receptor 1-related protein y (CR2-Crry, an in

53 We found that loss of polarity of complement receptor 1-related protein y (Crry) in the tu

54 ow that deleting the C3 convertase regulator complement receptor 1-related protein y (Crry) induces m

55 IL-17 differentially suppressed complement receptor 1-related protein y expression in ai

56 lement-regulatory protein (CRP) (CD55, CD46, complement receptor 1-related protein y/CD46) expression

57 se Cfh as the functional surrogate for human complement receptor 1.

58 C3 fragments on the organism from binding to complement receptor 1.

59 eraction of C3b with Factor B, Factor H, and complement receptor 1.

60 tibodies to block P. falciparum invasion via complement receptor 1.

61 mediated by NTS-DBL1alpha interactions with complement receptor 1.

62 Studies in complement receptor 1/2 (CR1/CR2)-deficient mice showed

63 g WNV infection in complement (C) 3(-/-) and complement receptor 1/2(-/-) mice.

64 complexes (ICs) from noncognate B cells via complement receptors 1 and 2 (CD35 and CD21, respectivel

65 d alone, an effect requiring the presence of complement receptors 1 and 2 (CR1/2).

66 Cr2, which encodes complement receptors 1 and 2 (CR1/CR2; CD35/CD21), is a

67 abeling of FDC reticula with FDC-M1 and anti-complement receptors 1 and 2 was preserved, indicating t

68 The level of FDC-M1, complement receptors 1 and 2, FcgammaRII, and FDC-M2 on

69 lly depleted of complement, or deficient for complement receptors 1 and 2, were also susceptible to s

70 mice deficient in C3 or in CD21/CD35 (i.e., complement receptors 1 and 2; CR1/CR2) were immunized wi

71 Soluble complement receptor-1 (20 mg/kg) was administered intrap

72 on with (99m)Technecium-labelled recombinant complement receptor 2 ((99m)Tc-rCR2), which specifically

73 ctivation through coengagment of the BCR and complement receptor 2 (CD21).

74 rough the interaction between complement and complement receptor 2 (CR2 [CD21]).

75 of complement component C3d with B or T cell complement receptor 2 (CR2 or CD21) is a link between in

76 inant mouse protein composed of domains from complement receptor 2 (CR2) and FH (CR2-FH) in two model

77 consisting of the iC3b/C3d-binding region of complement receptor 2 (CR2) and the inhibitory domain of

78 mia-reperfusion (IR)-induced damage requires complement receptor 2 (CR2) for generation of the approp

79 receptor(s), we found that App1 does bind to complement receptor 2 (CR2) in a dose-dependent manner.

80 eraction between complement fragment C3d and complement receptor 2 (CR2) is a key aspect of complemen

81 ntains the AP-inhibitory domain, linked to a complement receptor 2 (CR2) targeting fragment that bind

82 nking an iC3b/C3dg-binding fragment of mouse complement receptor 2 (CR2) to a mouse complement-inhibi

83 cantly enhanced when linked to a fragment of complement receptor 2 (CR2), a receptor that targets C3

84 We discovered that complement receptor 2 (CR2), classically known as a core

85 A positional candidate gene at 1q32.2, complement receptor 2 (CR2), is also a candidate in the

86 le of inhibiting the interaction of C3d with complement receptor 2 (CR2), which plays an important ro

87 The interaction of complement receptor 2 (CR2)--which is present on B cells

88 , targeted complement inhibition with either complement receptor 2 (CR2)-Crry (blocks all pathways at

89 Complement receptor 2 (CR2)-Crry inhibits complement act

90 We investigated the use of complement receptor 2 (CR2)-Crry, a complement inhibitor

91 Complement receptor 2 (CR2, CD21) is a cell membrane pro

92 Complement receptor 2 (CR2/CD21) is part of the B-cell c

93 nt that can facilitate the coligation of the complement receptor 2 (CR2/CD21) with the BCR via C3dg/A

94 that mediates attachment to B cells through complement receptor 2 (CR2/CD21).

95 Complement receptor 2 (CR2; CD21) is a membrane-bound re

96 The C3-binding domain of human complement receptor 2 (CR2; CD21) was linked to the comp

97 ect of a recombinant AP inhibitor containing complement receptor 2 and factor H (CR2-fH) on CAIA in m

98 ed in the lung and occurred independently of complement receptor 2 and Fcgamma receptors, but was dep

99 that contains the iC3b/C3d binding region of complement receptor 2 linked to the inhibitory region of

100 GT-/- mice were crossed with complement receptor 2 loci knockout mice to generate dou

101 via complement protein 3d and antigen to the complement receptor 2 signaling complex.

102 potential HIV-binding molecules FcRgammaIII, complement receptor 2, and various complement components

103 3) deficiency and complement inhibition with complement receptor 2-complement receptor 1-related prot

104 Complement receptor 2-deficient (Cr2(-/-)) mice are resi

105 Complement receptor 2-negative (CR2/CD21(-)) B cells hav

106 21/35(-/-) mice, deficient in CD21 and CD35 (complement receptors 2 and 1, respectively), were infect

107 omplement component C3 (C3d) and the modular complement receptor-2 (CR2) is important for cross-linki

108 rHDL attenuated the amount of CC-induced complement receptor 3 (CD11b/CD18) expression on monocyt

109 Ab blockade of the integrin complement receptor 3 (CD11b/CD18) significantly inhibit

110 e is dependent on beta-glucan recognition by complement receptor 3 (CD11b/CD18), but not Dectin-1, or

111 ement activation resulted in upregulation of complement receptor 3 (CD11b/CD18), leading to phagocyto

112 dition to the I-domain, the beta(2) integrin complement receptor 3 (CR3) (CD11b/CD18) contains a lect

113 gested that beta2 integrin receptors such as complement receptor 3 (CR3) and 4 (CR4) may act as novel

114 Complement receptor 3 (CR3) and CD36 have been suggested

115 Interestingly, we also found that both complement receptor 3 (CR3) and dectin-1 play a crucial

116 ggestive of binding to the lectin domains of complement receptor 3 (CR3) and dectin-1.

117 A role for both complement receptor 3 (CR3) and Fcgamma receptors in upt

118 Among AM receptors, complement receptor 3 (CR3) and FcRgamma are the most co

119 ized C albicans was found to be dependent on complement receptor 3 (CR3) and the signaling proteins p

120 Complement Receptor 3 (CR3) and Toll-like Receptor 2 (TL

121 s also unaffected in mice deficient in C3 or complement receptor 3 (CR3) but was almost completely ab

122 Neisseria gonorrhoeae can engage human complement receptor 3 (CR3) directly or through surface-

123 Small molecule antagonists to complement receptor 3 (CR3) have been widely sought, but

124 The macrophage mannose receptor (MR) and complement receptor 3 (CR3) have historically been consi

125 ls (HPCs) and the role of complement (C) and complement receptor 3 (CR3) in BM injury/repair.

126 we uncovered a novel role for the microglial complement receptor 3 (CR3) in the regulation of soluble

127 with the complement C3dg, can interact with complement receptor 3 (CR3) on activated monocytes, thus

128 ion resulted in reduced bacterial binding to complement receptor 3 (CR3) on the surface of murine mac

129 ial for beta2-induced accumulation of Rho at complement receptor 3 (CR3) phagosomes.

130 Complement receptor 3 (CR3), a genetic variant of which

131 ecifically iC3b production and engagement of complement receptor 3 (CR3), had a significant impact on

132 ophages isolated from mannose receptor (MR), complement receptor 3 (CR3), MyD88, Toll-like receptor 4

133 ional and oligomeric states: the BCR and the complement receptor 3 (CR3), on murine splenocytes, puri

134 identified complement receptor CRIg, but not complement receptor 3 (CR3), rescued DAF/Crry-deficient

135 These receptors include complement receptor 3 (CR3), used by promastigotes, and

136 ially binds an inactive form of the integrin complement receptor 3 (CR3), using a site outside of its

137 ed a phagocytic marker, via interaction with complement receptor 3 (CR3).

138 cytic cells, including the beta(2) integrin, complement receptor 3 (CR3).

139 rior studies indicated the ability of Abs to complement receptor 3 (CR3, CD11b/CD18) to suppress the

140 D209), Dectin-1, Toll-like receptors (TLRs), complement receptor 3 (CR3, CD11b/CD18), nucleotide olig

141 C. albicans mediated by the beta2 integrin, complement receptor 3 (CR3, CD11b/CD18, alphaMbeta2).

142 hers HPCs via the inserted (I) domain of HPC complement receptor 3 (CR3, CD11b/CD18, Mac-1).

143 Complement receptor 3 (CR3; also called CD11b/CD18), a b

144 the fimbriae of P. gingivalis interact with complement receptor 3 (CR3; CD11b/CD18) in monocytes/mac

145 been shown to function via the iC3b-receptor complement receptor 3 (CR3; CD11b/CD18) thereby enhancin

146 neutrophil opsonic receptors, FcgammaRs and complement receptor 3 (Mac-1) to cellular cytotoxic resp

147 We have shown previously that complement receptor 3 and Akt kinase play important role

148 roglial phagocytosis stimulated by fAbeta or complement receptor 3 and argue that this may, in part,

149 modulation of TLR8 signaling was mediated by complement receptor 3 and led to enhanced infection.

150 roduce a new picture of Fcgamma receptor and complement receptor 3 intracellular signaling have been

151 ae allowed P. gingivalis to exploit the TLR2/complement receptor 3 pathway for intracellular entry, i

152 oglia-specific phagocytic signaling pathway, complement receptor 3(CR3)/C3.

153 ITGAM encodes the integrin CD11b, a part of complement receptor 3, a novel candidate gene implicated

154 ly, attributable to failure to interact with complement receptor 3, although not with TLR2.

155 egrin (CD11b/CD18), macrophage-1 antigen, or complement receptor 3, as a cellular receptor for leukoc

156 ound to depend on beta-glucan recognition by complement receptor 3, require Fn and ERK but not ROS, a

157 MN with C5a led to upregulation of activated complement receptor 3, resulting in enhanced complement

158 complement receptor 3, resulting in enhanced complement receptor 3-dependent PMN-ADCC against tumor c

159 mma receptor internalization pathway but not complement receptor 3-dependent uptake, which is control

160 CyaA penetrates the complement receptor 3-expressing phagocytes and ablates

161 CyaA penetrates complement receptor 3-expressing phagocytes and catalyze

162 Furthermore, overexpressing stathmin reduces complement receptor 3-mediated phagocytosis and cellular

163 o inhibited by blocking Abs directed against complement receptor 3.

164 1 in macrophages that lack mannose receptor, complement receptors 3 and 4, type A scavenger receptor,

165 g, attributed to diminished AM expression of complement receptor-3 (CR3), which is exploited by P. gi

166 e desialylated neurites was mediated via the complement receptor-3 (CR3; CD11b/CD18).

167 CD11c/CD18 (alphaXbeta2, p150/95, or complement receptor 4, CR4) is a monocyte/macrophage-enr

168 s integrin-mediated phagocytosis through the complement receptor alpha(M)beta(2).

169 coexpressed with CD18 to form the Mac-1/CR3 complement receptor and adhesion molecule.

170 Using a fusion protein of a complement receptor and an IgG Fc fragment, therapeutic

171 3bBb).C3) interferes with the interaction of complement receptors and C3b.

172 possible effects of ANE on the expression of complement receptors and Fc receptors were examined usin

173 activation did not promote infection through complement receptors and inhibited anti-H IgG-mediated e

174 is by macrophages is strongly dependent upon complement receptors and upon serum with intact compleme

175 entiates among the contributions from Fc and complement receptors, and provides a tool for estimating

176 receptors and in conditions of FcgammaR and complement receptor blockage with specific Abs.

177 in 8 (aqp8), adrenomedullin receptor (admr), complement receptor C1qR-like (crl), scavenger receptor

178 All measures were reversed by blocking C3a complement receptor (C3aR), alternative complement pathw

179 ional roles for both C5a receptors, that is, complement receptor C5a (C5aR) and C5a receptor-like 2 (

180 Mice deficient in complement receptor C5a did not show increased MMP-9 act

181 d an intimate crosstalk between TLR2 and the complement receptor C5aR and can contribute to the persi

182 Crosstalk between the complement receptor C5aR and FcgammaRIIa on neutrophils

183 deficient in complement factor 5 (C5) or the complement receptor C5aR mounted robust IL-17A responses

184 Engagement of the complement receptor C5aR on neutrophils induces expressi

185 CXCR2 and CCR2 as targets for HlgAB, and the complement receptors C5aR and C5L2 as targets for HlgCB.

186 However, the distinct roles of the two complement receptors C5aR1 and C5aR2 in bone has to date

187 uman phagocytes through interaction with the complement receptors C5aR1 and C5aR2.

188 brane movement impedes the clustering of the complement receptor CD11b/CD18 on PMNs and, in turn, dec

189 the viral envelope glycoprotein gp350 to the complement receptor CD21.

190 radiation bone marrow-chimeric mice lacking complement receptors CD21 and CD35 on stromal cells elic

191 Mice lacking complement receptors CD21/35 partially resist terminal p

192 ts function in B cell activation through the complement receptors CD21/35.

193 These results suggest that complement receptors CD21/CD35 are important in maintena

194 In addition, complement receptors (CD21 and CD35) on B cells cooperat

195 binding of complement-tagged antigens to the complement receptor, CD21, and to the BCR.

196 human T cells, autocrine stimulation of the complement receptor CD46, and specifically its intracell

197 t inhibitor linked to a C3 binding region of complement receptor (CR) 2 were prepared and characteriz

198 Follicular dendritic cells (FDCs) and complement receptor (Cr)1 and complement receptor (Cr)2

199 lls (FDCs) and complement receptor (Cr)1 and complement receptor (Cr)2 are important for the generati

200 Notably, blocking complement receptor (CR)3 significantly reduced Aspergil

201 complement-decorated pathogens with various complement receptors (CR) on phagocytes.

202 Complement and complement receptors (CR) play a central role in immune

203 Complement receptors (CR), CR3 (CD11b), and CR4 (CD11c)

204 Cr2(-/-) mice, deficient in complement receptors (CR)1 and CR2, demonstrate defects

205 terium kansasii enter macrophages, using the complement receptors CR1, CR3, CR4, and the mannose rece

206 Our new results suggest that complement receptors CR1/2, CR3, and CR4 all play import

207 n, but not murine, erythrocytes also present complement receptor (CR1), which binds Ad5 in the presen

208 NE significantly inhibited the production of complement receptors (CR1, CR3, and CR4) and Fc receptor

209 otypes resulted from polymorphisms in the C3 complement receptor Cr2 gene.

210 ulating humoral immunity largely through the complement receptor CR2, which forms a coreceptor on B c

211 hagocytosis, altered the distribution of the complement receptor CR3 (CD11b/CD18), enhanced the intra

212 The complement receptor CR3 (CD11b/CD18, Mac-1) mediates the

213 Inhibition of C1q, C3, or the microglial complement receptor CR3 reduces the number of phagocytic

214 cteria from the mannose receptor (MR) to the complement receptor CR3, the scavenger receptor A (SRA),

215 Host immune cells use type 3 complement receptors (CR3) to regulate excess TNF-alpha

216 ing or gene ablation of the newly identified complement receptor CRIg, but not complement receptor 3

217 Complement receptors (CRs) CD21 and CD35 form a corecept

218 the individual roles of the alphavbeta5 and complement receptors (CRs) in the phagocytosis and induc

219 B cells express complement receptors (CRs) that bind activated fragments

220 Complement receptors (CRs), expressed notably on myeloid

221 ptors (FcRs; FcR, Fc receptor) and the other complement receptors (CRs), mediate binding and ingestio

222 B cells captured immune complexes by a complement receptor-dependent mechanism from macrophage

223 CRIg, a complement receptor expressed on macrophages, binds to C

224 ly, deficiency of CRIg, CR3, and other known complement receptors failed to prevent Crry-deficient er

225 y result from reduction of the expression of complement receptors, Fc receptors, and F-actin formatio

226 Expression of complement receptors, Fc receptors, and F-actin in ANE-t

227 gC1qR, a complement receptor for C1q, plays a pivotal role in the

228 Integrin alpha(X)beta(2) functions as complement receptor for iC3b and mediates recognition an

229 hages (M/M(Phi)s) through interaction with a complement receptor gC1qR.

230 is substantiated by studies indicating that complement receptor genes are within major susceptibilit

231 The complement receptor Ig (CRIg) is selectively expressed b

232 The CD21/35 proteins are complement receptors implicated in controlling and inter

233 tosis involves ingestion through both Fc and complement receptors in the absence of complement.

234 reactive antibodies, we examined the role of complement receptors in the production of alphaGal-speci

235 ocytic index was caused by interference with complement receptor ingestion as a consequence of satura

236 t role in clearing particles in circulation, complement receptors involved in this process have yet t

237 m, via inhibition of Toll-like receptor- and complement receptor-mediated activation.

238 by the alternative pathway of complement via complement receptor-mediated erythrophagocytosis in the

239 , we examined the role of SP-A in modulating complement receptor-mediated phagocytosis.

240 ved MPhi, we now identify CD11b as the major complement receptor mediating MPhi adherence to the larv

241 These mechanisms are mediated by the complement receptor of immunoglobulin family (CRIg).

242 e was recently independently identified as a complement receptor of the Ig superfamily (CRIg) and was

243 a targeted complement inhibitor, comprising complement receptor of the Ig superfamily (CRIg) fused w

244 A complement receptor of the Ig superfamily (CRIg) is expr

245 rophages characterized by high expression of complement receptor of the Ig superfamily (CRIg), a rece

246 SPECT/muCT) imaging using Nanobodies against complement receptor of the Ig superfamily (CRIg), found

247 lated with disease protection, including the complement receptor of the immunoglobulin superfamily (C

248 Previously, we have shown that human complement receptor of the immunoglobulin superfamily (C

249 pture of bacteria-platelet-complexes via the complement receptor of the immunoglobulin superfamily, C

250 the identification and characterization of a Complement Receptor of the Immunoglobulin superfamily, C

251 tulated that surface-bound C3 interacts with complement receptors on alloreactive T cells or on antig

252 nsported into B cell follicles by binding to complement receptors on B cells.

253 We evaluated the expression of several complement receptors on cDCs and confirmed that cDCs tha

254 otein, resulting in enhanced phagocytosis by complement receptors on human alveolar macrophages.

255 lement complex and lowered the expression of complement receptors on monocytes in whole blood in resp

256 platelets and erythrocytes engage different complement receptors on tissue macrophages in vivo.

257 on the particle surface serve as targets for complement receptors present on phagocytic cells.

258 tic index but increased phagocytosis through complement receptors rapidly compensated for this effect

259 ment and neurodegeneration, we asked whether complement receptors regulate neurogenesis.

260 m of the mouse membrane complement inhibitor complement receptor-related gene y (Crry) fused to the I

261 eal injection of cobra venom factor (CVF) or complement receptor-related gene y (Crry)-Ig, a potent C

262 Complement receptor-related gene/protein y (Crry) is a c

263 nhibition of C3 by overexpression of soluble complement receptor-related protein y in an AD mouse mod

264 hanism and the possible involvement of other complement receptors remain unclear.

265 igated whether App1 would also bind to other complement receptor(s), we found that App1 does bind to

266 zing complement regulator derived from human complement receptor type 1 (APT070) and then subjected t

267 (tPA) to a monoclonal antibody (mAb) against complement receptor type 1 (CR1) expressed primarily on

268 Complement receptor type 1 (CR1) is a membrane receptor

269 Human complement receptor type 1 (CR1, CD35) is a type I membr

270 4) on the merozoite surface interacting with complement receptor type 1 (CR1, CD35) on the erythrocyt

271 The extracellular domain of the complement receptor type 1 (CR1; CD35) consists entirely

272 retreated with C1 inhibitor (n=5) or soluble complement receptor type 1 (n=6) at unchanged flow condi

273 ndertaken to determine whether soluble human complement receptor type 1 (TP10), a potent inhibitor of

274 l was significantly prolonged in the soluble complement receptor type 1 group (36 min, CI: 26-46) (P<

275 A structural comparison between Crry and complement receptor type 1 indicated that the domain arr

276 resence of a cofactor such as factor H (fH), complement receptor type 1, membrane cofactor protein, o

277 Human complement receptor type 2 (CD21) is the cellular recept

278 Human complement receptor type 2 (CR2 and CD21) is a cell memb

279 The interactions between the complement receptor type 2 (CR2) and the C3 complement f

280 complement regulator (SCR) domains, whereas complement receptor type 2 (CR2) has 15 SCR domains and

281 the Epstein-Barr virus glycoprotein gp350 by complement receptor type 2 (CR2) is critical for viral a

282 short complement regulator (SCR) domains of complement receptor type 2 (CR2) that bind to complement

283 protein containing the C3d-binding region of complement receptor type 2 (CR2) was then conjugated to

284 irst two short consensus repeats (SCR1-2) of complement receptor type 2 (CR2, CD21) and C3d in soluti

285 Complement receptor type 2 (CR2, CD21) forms a tight com

286 Complement receptor type 2 (CR2, CD21) is a cell surface

287 Complement receptor type 2 (CR2, CD21) is a cell surface

288 therapeutic fusion protein linking the human complement receptor type 2 (CR2/CD21) C3 fragment (C3fra

289 Human complement receptor type 2 (CR2/CD21) is a B lymphocyte

290 Complement receptor type 2 (CR2/CD21) is essential for t

291 Complement receptor type 2 (CR2/CD21), in association wi

292 d and inactivated C3b, which are ligands for complement receptor type 2 (CR2/CD21), the aim of the cu

293 C3dg adducts of Ag can coligate complement receptor type 2 (CR2; CD21) and the B cell Ag

294 s that is recognized by Mphi, purified human complement receptor type 3 (CR3, CD11b/CD18) was used to

295 the complement C3 activation product iC3b to complement receptor type 3 (the iC3b receptor) on antige

296 ar the CD11b/CD18 beta2 integrin heterodimer complement receptor type 3/Mac-1.

297 with an alphaI domain, alpha(X)beta(2), the complement receptor type 4.

298 (MCP), decay accelerating factor (DAF), and complement receptors type 1 (CR1) and 2 (CR2).

299 e the antibody response in mice deficient in complement receptor types 1 and 2 (CR1 and CR2) has rais

300 To further characterize complement and complement receptors, we have identified a role for C3 i